Even though the expression of PD-L1 in serum could be an essential biomarker for selecting breast cancer patients with immunotherapy, it must be compared with the current standard of care for determining patients for atezolizumab treatment and be established from a clinical trial. This evidence concerns the gene CD274 and breast carcinoma.